Aurinia Pharmaceuticals (NASDAQ:AUPH) saw its shares surge 5.03% in Friday's intraday trading, following the company's release of its full-year 2024 financial results that exceeded analysts' earnings expectations.
The biotechnology firm reported revenue of $235.1 million for 2024, up 34% year-over-year and in line with estimates. However, Aurinia delivered a notable earnings beat, with earnings per share (EPS) of $0.04 surpassing analyst projections by 54%.
The strong earnings performance marked a significant turnaround for Aurinia, as the company reported a net income of $5.75 million in 2024, compared to a net loss of $78 million in the previous year. The company's profit margin also improved to 2.4%, up from a net loss position in 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.